Porton Pharma Solutions Ltd

Established in 2005 as a CMO with global ambitions, Porton Pharma Solutions Ltd. is a service provider and manufacturer of chiral intermediates and other excipients, offering CRO, CMO and CDMO contract services to markets across North America, Western Europe, Asia, Australasia, the Middle East, Africa and Latin America. The company opened its first manufacturing facility in Changshou, Chongqing in 2006 alongside process R&D centers in Chongqing and Chengdu, launched its Porton-up program and passed its first cGMP audit by a global pharmaceutical company in 2009, was listed on the Shenzhen Stock Exchange (stock code 300363) in 2014, passed its first US FDA audit in 2015, and acquired USA-based J-Star Research in 2017 to expand its CRO service while opening a new global headquarters and process technology center in Chongqing. It formed an exclusive bio-catalysis technology partnership with Codexis in 2018 and renamed itself Porton Pharma Solutions Ltd. while launching its Biologics CDMO unit, Suzhou Porton Biologics; in 2019 it passed an EMA audit and a second US FDA audit, was named among the Top 20 CRO Enterprises in China, and launched its Drug Product CDMO unit, Porton Pharmaceutical Co., Ltd. The company offers OEM production and is recognized for brand strength, international approvals, an experienced R&D staff, production capacity, a large product line and strong industry reputation.